<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="EN" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Neurol</journal-id>
      <journal-title>Journal of Neurology</journal-title>
      <issn pub-type="ppub">0340-5354</issn>
      <issn pub-type="epub">1432-1459</issn>
      <publisher>
        <publisher-name>Steinkopff-Verlag</publisher-name>
        <publisher-loc>Darmstadt</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17401736</article-id>
      <article-id pub-id-type="pmc">2778698</article-id>
      <article-id pub-id-type="publisher-id">521</article-id>
      <article-id pub-id-type="doi">10.1007/s00415-006-0521-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editors</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Return of meningeal symptoms in a patient treated for cryptococcal meningitis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Huits</surname>
            <given-names>Ralph M. H. G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bremmer</surname>
            <given-names>Rosetta</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Enting</surname>
            <given-names>Roelien H.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sprenger</surname>
            <given-names>Herman G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>van Assen</surname>
            <given-names>Sander</given-names>
          </name>
          <address>
            <phone>+31-50-3612350</phone>
            <fax>+31-50-3619069</fax>
            <email>s.van.assen@int.umcg.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Dept. of Internal Medicine, Division of Infectious Diseases, University Medical Center Groningen, Postbus 30001, 9700 RB Groningen, The Netherlands </aff>
        <aff id="Aff2"><label>2</label>Dept. of Neurology, University Medical Center Groningen, Groningen, The Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>2</day>
        <month>4</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>10</month>
        <year>2007</year>
      </pub-date>
      <volume>254</volume>
      <issue>10</issue>
      <fpage>1443</fpage>
      <lpage>1444</lpage>
      <history>
        <date date-type="received">
          <day>6</day>
          <month>9</month>
          <year>2006</year>
        </date>
        <date date-type="rev-recd">
          <day>5</day>
          <month>12</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>12</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Steinkopff-Verlag 2007</copyright-statement>
      </permissions>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Steinkopff-Verlag 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <p>Sirs: A 28-year-old Guinese man was admitted to our hospital with a 3-week history of severe headache, vomiting and fever. Ten months earlier he was diagnosed with AIDS. The presenting AIDS-defining illness then, was disseminated cryptococcosis: <italic>Cryptococcus neoformans</italic> had been recovered from CSF, bronchoalveolar washings, and blood. Standard treatment of CM with amphotericin B and flucytosine followed by fluconazole [<xref ref-type="bibr" rid="CR1">1</xref>] resulted in clinical and microbiological cure. The patient had been taking fluconazole 200 mg QD PO as secondary prophylaxis since. After successful treatment of CM, HAART was initiated. This preceded admission by 320 days. The CD4 cell count rose from 0 to 120 cells/&#xB5;l and HIV1-RNA to undetectable levels (&lt;50 copies/ ml). There was no reason to doubt compliance to fluconazole prophylaxis.</p>
    <p>On examination an ill-looking man was seen, with low-grade pyrexia and stable haemodynamics. He was alert and cooperative, with no signs of meningism or mental confusion. Neurological examination and further physical examination revealed no abnormalities. Laboratory results were unremarkable. Brain CT-scan without contrast did not show any mass lesions, or hydrocephalus. Clear CSF was obtained, opening pressure was &gt;50 cm H<sub>2</sub>O. CSF contained 0.59 g/l protein, 3.0 mmol/l glucose (at a serum glucose concentration of 5.1 mmol/l) and 272 &#xD7; 10<sup>6</sup>/l leukocytes, mainly monocytic. It tested positive for cryptococcal antigen. Considering relapse CM, treatment appropriate to this diagnosis was initiated (amphotericin B 1 mg/kg intravenously per day and flucytosine 100 mg/ kg/d PO).</p>
    <p>After 1 week his headache and malaise had not improved. Both stain and culture were negative for <italic>Cryptococcus neoformans</italic>. Cryptococcal antigen titers were found to be low: 1:16 in serum and 1:4 in CSF. Therefore the diagnosis was revised to <italic>Cryptococcus neoformans</italic>-related immune reconstitution inflammatory syndrome (IRIS).</p>
    <p>Antifungal treatment was discontinued and prednisone was prescribed (1 mg/kg/day IV).</p>
    <p>One more lumbar puncture was needed for temporary relief of symptoms due to raised CSF pressure. Our patient made a dramatic recovery and was discharged from hospital 3 days later, symptom-free. Prednisone was tapered in 4 months.</p>
    <p>IRIS can manifest itself as a latent infection unmasked by immune reconstitution, or as sterile inflammation in response to persisting antigens of an infection already treated. Therefore, latent infection should be ruled out in patients commencing antiretroviral therapy.</p>
    <p>Key to the diagnosis of cryptococcal-related IRIS in patients treated with HAART is the absence of fungal cells in all cultures. Cryptococcal antigen in blood or CSF of HIV-infected patients previously treated for CM, is a poor marker of infection [<xref ref-type="bibr" rid="CR2">2</xref>]. Shelburne et al. found low cryptococcal antigen titres of value in discriminating cryptococcal-related IRIS from CM in a retrospective cohort study [<xref ref-type="bibr" rid="CR3">3</xref>]. Other factors predictive of cryptococcal-related IRIS are a higher white blood cell count in CSF, higher CSF glucose and a higher CD4 cell count. . Lumbar puncture opening pressure was significantly higher in the IRIS group. These findings reflect the inflammatory nature of the syndrome due to immune restoration. The presence of the following risk factors for IRIS support the diagnosis in this case: a rise in CD4 cell count, a decrease in viral load, and compliance with a secondary prophylactic treatment regime of fluconazole.</p>
    <p>For treatment of the aseptic meningitis, anti-inflammatory drugs are a logical choice. Short-term corticosteroid administration was shown to be safe and well tolerated in patients who are receiving antiretroviral treatment [<xref ref-type="bibr" rid="CR4">4</xref>]. It proved beneficial to prevent paradoxical reactions in tuberculous meningitis [<xref ref-type="bibr" rid="CR5">5</xref>] and in other described cases of cryptococcal meningitis associated IRIS [<xref ref-type="bibr" rid="CR6">6</xref>]. At a dose of 60 mg prednisone IV, our patient responded well. However, studies defining the role of corticosteroids in IRIS are urgently needed. The use of corticosteroids was demonstrated to be harmful in CM or cryptococcoma [<xref ref-type="bibr" rid="CR7">7</xref>]. Therefore, exclusion of active cryptococcal disease remains the most important step in managing <italic>Cryptococcus neoformans</italic>&#x2014;related IRIS.</p>
    <p>Guidelines for the treatment of CM recommend daily lumbar punctures in all patients with initially elevated opening pressures (&gt;25 cm H<sub>2</sub>O) until the pressure is adequately controlled [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Since the mechanism for increased intracranial pressure is thought to be the same in CM and cryptococcal IRIS, adherence to these guidelines seems prudent.</p>
    <p>Concluding, the HIV-positive patient treated with highly active antiretroviral therapy and returning meningeal symptoms after treatment for cryptococcal meningitis is diagnostically challenging. Distinguishing between <italic>Cryptococcus neoformans</italic>-related IRIS and active cryptococcal disease as two different clinical entities is crucial.</p>
  </body>
  <back>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saag</surname>
            </name>
          </person-group>
          <source>Clin Infect Dis</source>
          <year>2000</year>
          <volume>30</volume>
          <fpage>710</fpage>
          <pub-id pub-id-type="doi">10.1086/313757</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Saag MS, Graybill RJ, Larsen RA, Pappas
PG, Perfect JR, Powderly WG, Sobel JD,
Dismukes WE (2000) Practice guidelines
for the management of cryptococcal
disease. Infectious Diseases Society of
America. Clin Infect Dis 30:710&#x2013;718 <pub-id pub-id-type="pmid">10770733</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Powderly</surname>
            </name>
          </person-group>
          <source>Clin Infect Dis</source>
          <year>1994</year>
          <volume>18</volume>
          <fpage>789</fpage>
        </citation>
        <citation citation-type="display-unstructured">Powderly WG, Cloud GA, Dismukes WE,
Saag MS (1994) Measurement of cryptococcal
antigen in serum and cerebrospinal
fluid: value in the management of
AIDS-associated cryptococcal meningitis.
Clin Infect Dis 18:789&#x2013;792 <pub-id pub-id-type="pmid">8075272</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shelburne</surname>
            </name>
          </person-group>
          <source>Clin Infect Dis</source>
          <year>2005</year>
          <volume>40</volume>
          <fpage>1049</fpage>
          <pub-id pub-id-type="doi">10.1086/428618</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shelburne SA III, Darcourt J, White AC
Jr., Greenberg SB, Hamill RJ, Atmar RL,
Visnegarwala F (2005) The role of immune
reconstitution inflammatory syndrome
in AIDS-related Cryptococcus
neoformans disease in the era of highly
active antiretroviral therapy. Clin Infect
Dis 40:1049&#x2013;1052 <pub-id pub-id-type="pmid">15825000</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McComsey</surname>
            </name>
          </person-group>
          <source>AIDS</source>
          <year>2001</year>
          <volume>15</volume>
          <fpage>321</fpage>
          <pub-id pub-id-type="doi">10.1097/00002030-200102160-00004</pub-id>
        </citation>
        <citation citation-type="display-unstructured">McComsey GA, Whalen CC, Mawhorter
SD, Asaad R, Valdez H, Patki AH,
Klaumunzner J, Gopalakrishna KV,
Calabrese LH, Lederman MM (2001)
Placebo-controlled trial of prednisone in
advanced HIV-1 infection. AIDS 15:321&#x2013;327 <pub-id pub-id-type="pmid">11273211</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thwaites</surname>
            </name>
          </person-group>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>351</volume>
          <fpage>1741</fpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa040573</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Thwaites GE, Nguyen DB, Nguyen HD,
Hoang TQ, Do TT, Nguyen TC, Nguyen
QH, Nguyen TT, Nguyen NH, Nguyen
TN, Nguyen NL, Nguyen HD, Vu NT,
Cao HH, Tran TH, Pham PM, Nguyen
TD, Stepniewska K, White NJ, Tran TH,
Farrar JJ (2004) Dexamethasone for the
treatment of tuberculous meningitis in
adolescents and adults. N Engl J Med
351:1741&#x2013;1751 <pub-id pub-id-type="pmid">15496623</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Venkataramana</surname>
            </name>
          </person-group>
          <source>Neurology</source>
          <year>2006</year>
          <volume>67</volume>
          <fpage>383</fpage>
          <pub-id pub-id-type="doi">10.1212/01.wnl.0000227922.22293.93</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Venkataramana A, Pardo CA, McArthur
JC, Kerr DA, Irani DN, Griffin JW, Burger
P, Reich DS, Calabresi PA, Nath A
(2006) Immune reconstitution inflammatory
syndrome in the CNS of HIV-infected
patients. Neurology 67:383&#x2013;388 <pub-id pub-id-type="pmid">16894096</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Graybill</surname>
            </name>
          </person-group>
          <source>Clin Infect
Dis</source>
          <year>2000</year>
          <volume>30</volume>
          <fpage>47</fpage>
          <pub-id pub-id-type="doi">10.1086/313603</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Graybill JR, Sobel J, Saag M, van Der HC,
Powderly W, Cloud G, Riser L, Hamill R,
Dismukes W (2000) Diagnosis and
management of increased intracranial
pressure in patients with AIDS and
cryptococcal meningitis. The NIAID
Mycoses Study Group and AIDS Cooperative
Treatment Groups. Clin Infect
Dis 30:47&#x2013;54 <pub-id pub-id-type="pmid">10619732</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
